Locally advanced epithelial sinonasal tumors: The impact of multimodal approach

Objective Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. Methods We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated...

Full description

Saved in:
Bibliographic Details
Published in:The Laryngoscope 2020-04, Vol.130 (4), p.857-865
Main Authors: Orlandi, Ester, Cavalieri, Stefano, Granata, Roberta, Nicolai, Piero, Castelnuovo, Paolo, Piazza, Cesare, Schreiber, Alberto, Turri‐Zanoni, Mario, Quattrone, Pasquale, Miceli, Rosalba, Infante, Gabriele, Sessa, Fausto, Facco, Carla, Calareso, Giuseppina, Iacovelli, Nicola Alessandro, Mattavelli, Davide, Paderno, Alberto, Resteghini, Carlo, Locati, Laura Deborah, Licitra, Lisa, Bossi, Paolo
Format: Article
Language:English
Subjects:
Chemotherapy
Head & neck cancer
induction chemotherapy
Medical prognosis
multimodal treatment
radiation
Sinonasal cancer
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3572-8fb833f153996a5084400a909badb073b541a2f744ebbe71b571e70cca62214f3
cites cdi_FETCH-LOGICAL-c3572-8fb833f153996a5084400a909badb073b541a2f744ebbe71b571e70cca62214f3
container_end_page 865
container_issue 4
container_start_page 857
container_title The Laryngoscope
container_volume 130
creator Orlandi, Ester
Cavalieri, Stefano
Granata, Roberta
Nicolai, Piero
Castelnuovo, Paolo
Piazza, Cesare
Schreiber, Alberto
Turri‐Zanoni, Mario
Quattrone, Pasquale
Miceli, Rosalba
Infante, Gabriele
Sessa, Fausto
Facco, Carla
Calareso, Giuseppina
Iacovelli, Nicola Alessandro
Mattavelli, Davide
Paderno, Alberto
Resteghini, Carlo
Locati, Laura Deborah
Licitra, Lisa
Bossi, Paolo
description Objective Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. Methods We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum‐based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. Results We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease‐free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P
doi_str_mv 10.1002/lary.28202
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2267742925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2378200450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3572-8fb833f153996a5084400a909badb073b541a2f744ebbe71b571e70cca62214f3</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobk5v_AFS8EaEznw2rXdj-AWDgUzQq5CmKctIm9q0yv69mZ1eeOHVOXAe3vPyAHCO4BRBiG-sbLdTnGKID8AYMYJimmXsEIzDkcQpw68jcOL9BkLECYPHYEQQSTLEkjFYLpyS1m4jWXzIWuki0o3p1toaaSNvaldLH7aur1zrb6PVWkemaqTqIldGVW87U7kiALJpWifV-hQcldJ6fbafE_Byf7eaP8aL5cPTfLaIFWEcx2mZp4SUoWyWJZLBlFIIZQazXBY55CRnFElcckp1nmuOcsaR5lApmWCMaEkm4GrIDW_fe-07URmvtLWy1q73AuOEc4ozzAJ6-QfduL6tQzuBCQ_aIGUwUNcDpVrnfatL0bSmCmYFgmKnWew0i2_NAb7YR_Z5pYtf9MdrANAAfBqrt_9EicXs-W0I_QJ82YbY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2378200450</pqid></control><display><type>article</type><title>Locally advanced epithelial sinonasal tumors: The impact of multimodal approach</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Orlandi, Ester ; Cavalieri, Stefano ; Granata, Roberta ; Nicolai, Piero ; Castelnuovo, Paolo ; Piazza, Cesare ; Schreiber, Alberto ; Turri‐Zanoni, Mario ; Quattrone, Pasquale ; Miceli, Rosalba ; Infante, Gabriele ; Sessa, Fausto ; Facco, Carla ; Calareso, Giuseppina ; Iacovelli, Nicola Alessandro ; Mattavelli, Davide ; Paderno, Alberto ; Resteghini, Carlo ; Locati, Laura Deborah ; Licitra, Lisa ; Bossi, Paolo</creator><creatorcontrib>Orlandi, Ester ; Cavalieri, Stefano ; Granata, Roberta ; Nicolai, Piero ; Castelnuovo, Paolo ; Piazza, Cesare ; Schreiber, Alberto ; Turri‐Zanoni, Mario ; Quattrone, Pasquale ; Miceli, Rosalba ; Infante, Gabriele ; Sessa, Fausto ; Facco, Carla ; Calareso, Giuseppina ; Iacovelli, Nicola Alessandro ; Mattavelli, Davide ; Paderno, Alberto ; Resteghini, Carlo ; Locati, Laura Deborah ; Licitra, Lisa ; Bossi, Paolo</creatorcontrib><description>Objective Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. Methods We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum‐based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. Results We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease‐free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P &lt; 0.0001). Conclusion Globally, the prognosis of locally advanced epithelial sinonasal cancers is dismal, with worse outcomes for neuroendocrine lesions. In the recurrent setting, feasibility of salvage surgery and clinical benefit from palliative chemotherapy are associated with longer OS. A multimodal treatment strategy with IC seems to offer improved OS when compared with other retrospective series not employing such a therapeutic tool. Level of Evidence 4 Laryngoscope, 130:857–865, 2020</description><identifier>ISSN: 0023-852X</identifier><identifier>EISSN: 1531-4995</identifier><identifier>DOI: 10.1002/lary.28202</identifier><identifier>PMID: 31369156</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Chemotherapy ; Head &amp; neck cancer ; induction chemotherapy ; Medical prognosis ; multimodal treatment ; radiation ; Sinonasal cancer ; Surgery</subject><ispartof>The Laryngoscope, 2020-04, Vol.130 (4), p.857-865</ispartof><rights>2019 The American Laryngological, Rhinological and Otological Society, Inc.</rights><rights>2020 The American Laryngological, Rhinological and Otological Society, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3572-8fb833f153996a5084400a909badb073b541a2f744ebbe71b571e70cca62214f3</citedby><cites>FETCH-LOGICAL-c3572-8fb833f153996a5084400a909badb073b541a2f744ebbe71b571e70cca62214f3</cites><orcidid>0000-0003-1294-6859 ; 0000-0002-5184-6140 ; 0000-0002-1580-3928</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31369156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orlandi, Ester</creatorcontrib><creatorcontrib>Cavalieri, Stefano</creatorcontrib><creatorcontrib>Granata, Roberta</creatorcontrib><creatorcontrib>Nicolai, Piero</creatorcontrib><creatorcontrib>Castelnuovo, Paolo</creatorcontrib><creatorcontrib>Piazza, Cesare</creatorcontrib><creatorcontrib>Schreiber, Alberto</creatorcontrib><creatorcontrib>Turri‐Zanoni, Mario</creatorcontrib><creatorcontrib>Quattrone, Pasquale</creatorcontrib><creatorcontrib>Miceli, Rosalba</creatorcontrib><creatorcontrib>Infante, Gabriele</creatorcontrib><creatorcontrib>Sessa, Fausto</creatorcontrib><creatorcontrib>Facco, Carla</creatorcontrib><creatorcontrib>Calareso, Giuseppina</creatorcontrib><creatorcontrib>Iacovelli, Nicola Alessandro</creatorcontrib><creatorcontrib>Mattavelli, Davide</creatorcontrib><creatorcontrib>Paderno, Alberto</creatorcontrib><creatorcontrib>Resteghini, Carlo</creatorcontrib><creatorcontrib>Locati, Laura Deborah</creatorcontrib><creatorcontrib>Licitra, Lisa</creatorcontrib><creatorcontrib>Bossi, Paolo</creatorcontrib><title>Locally advanced epithelial sinonasal tumors: The impact of multimodal approach</title><title>The Laryngoscope</title><addtitle>Laryngoscope</addtitle><description>Objective Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. Methods We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum‐based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. Results We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease‐free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P &lt; 0.0001). Conclusion Globally, the prognosis of locally advanced epithelial sinonasal cancers is dismal, with worse outcomes for neuroendocrine lesions. In the recurrent setting, feasibility of salvage surgery and clinical benefit from palliative chemotherapy are associated with longer OS. A multimodal treatment strategy with IC seems to offer improved OS when compared with other retrospective series not employing such a therapeutic tool. Level of Evidence 4 Laryngoscope, 130:857–865, 2020</description><subject>Chemotherapy</subject><subject>Head &amp; neck cancer</subject><subject>induction chemotherapy</subject><subject>Medical prognosis</subject><subject>multimodal treatment</subject><subject>radiation</subject><subject>Sinonasal cancer</subject><subject>Surgery</subject><issn>0023-852X</issn><issn>1531-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kF1LwzAUhoMobk5v_AFS8EaEznw2rXdj-AWDgUzQq5CmKctIm9q0yv69mZ1eeOHVOXAe3vPyAHCO4BRBiG-sbLdTnGKID8AYMYJimmXsEIzDkcQpw68jcOL9BkLECYPHYEQQSTLEkjFYLpyS1m4jWXzIWuki0o3p1toaaSNvaldLH7aur1zrb6PVWkemaqTqIldGVW87U7kiALJpWifV-hQcldJ6fbafE_Byf7eaP8aL5cPTfLaIFWEcx2mZp4SUoWyWJZLBlFIIZQazXBY55CRnFElcckp1nmuOcsaR5lApmWCMaEkm4GrIDW_fe-07URmvtLWy1q73AuOEc4ozzAJ6-QfduL6tQzuBCQ_aIGUwUNcDpVrnfatL0bSmCmYFgmKnWew0i2_NAb7YR_Z5pYtf9MdrANAAfBqrt_9EicXs-W0I_QJ82YbY</recordid><startdate>202004</startdate><enddate>202004</enddate><creator>Orlandi, Ester</creator><creator>Cavalieri, Stefano</creator><creator>Granata, Roberta</creator><creator>Nicolai, Piero</creator><creator>Castelnuovo, Paolo</creator><creator>Piazza, Cesare</creator><creator>Schreiber, Alberto</creator><creator>Turri‐Zanoni, Mario</creator><creator>Quattrone, Pasquale</creator><creator>Miceli, Rosalba</creator><creator>Infante, Gabriele</creator><creator>Sessa, Fausto</creator><creator>Facco, Carla</creator><creator>Calareso, Giuseppina</creator><creator>Iacovelli, Nicola Alessandro</creator><creator>Mattavelli, Davide</creator><creator>Paderno, Alberto</creator><creator>Resteghini, Carlo</creator><creator>Locati, Laura Deborah</creator><creator>Licitra, Lisa</creator><creator>Bossi, Paolo</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1294-6859</orcidid><orcidid>https://orcid.org/0000-0002-5184-6140</orcidid><orcidid>https://orcid.org/0000-0002-1580-3928</orcidid></search><sort><creationdate>202004</creationdate><title>Locally advanced epithelial sinonasal tumors: The impact of multimodal approach</title><author>Orlandi, Ester ; Cavalieri, Stefano ; Granata, Roberta ; Nicolai, Piero ; Castelnuovo, Paolo ; Piazza, Cesare ; Schreiber, Alberto ; Turri‐Zanoni, Mario ; Quattrone, Pasquale ; Miceli, Rosalba ; Infante, Gabriele ; Sessa, Fausto ; Facco, Carla ; Calareso, Giuseppina ; Iacovelli, Nicola Alessandro ; Mattavelli, Davide ; Paderno, Alberto ; Resteghini, Carlo ; Locati, Laura Deborah ; Licitra, Lisa ; Bossi, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3572-8fb833f153996a5084400a909badb073b541a2f744ebbe71b571e70cca62214f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chemotherapy</topic><topic>Head &amp; neck cancer</topic><topic>induction chemotherapy</topic><topic>Medical prognosis</topic><topic>multimodal treatment</topic><topic>radiation</topic><topic>Sinonasal cancer</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orlandi, Ester</creatorcontrib><creatorcontrib>Cavalieri, Stefano</creatorcontrib><creatorcontrib>Granata, Roberta</creatorcontrib><creatorcontrib>Nicolai, Piero</creatorcontrib><creatorcontrib>Castelnuovo, Paolo</creatorcontrib><creatorcontrib>Piazza, Cesare</creatorcontrib><creatorcontrib>Schreiber, Alberto</creatorcontrib><creatorcontrib>Turri‐Zanoni, Mario</creatorcontrib><creatorcontrib>Quattrone, Pasquale</creatorcontrib><creatorcontrib>Miceli, Rosalba</creatorcontrib><creatorcontrib>Infante, Gabriele</creatorcontrib><creatorcontrib>Sessa, Fausto</creatorcontrib><creatorcontrib>Facco, Carla</creatorcontrib><creatorcontrib>Calareso, Giuseppina</creatorcontrib><creatorcontrib>Iacovelli, Nicola Alessandro</creatorcontrib><creatorcontrib>Mattavelli, Davide</creatorcontrib><creatorcontrib>Paderno, Alberto</creatorcontrib><creatorcontrib>Resteghini, Carlo</creatorcontrib><creatorcontrib>Locati, Laura Deborah</creatorcontrib><creatorcontrib>Licitra, Lisa</creatorcontrib><creatorcontrib>Bossi, Paolo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The Laryngoscope</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orlandi, Ester</au><au>Cavalieri, Stefano</au><au>Granata, Roberta</au><au>Nicolai, Piero</au><au>Castelnuovo, Paolo</au><au>Piazza, Cesare</au><au>Schreiber, Alberto</au><au>Turri‐Zanoni, Mario</au><au>Quattrone, Pasquale</au><au>Miceli, Rosalba</au><au>Infante, Gabriele</au><au>Sessa, Fausto</au><au>Facco, Carla</au><au>Calareso, Giuseppina</au><au>Iacovelli, Nicola Alessandro</au><au>Mattavelli, Davide</au><au>Paderno, Alberto</au><au>Resteghini, Carlo</au><au>Locati, Laura Deborah</au><au>Licitra, Lisa</au><au>Bossi, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Locally advanced epithelial sinonasal tumors: The impact of multimodal approach</atitle><jtitle>The Laryngoscope</jtitle><addtitle>Laryngoscope</addtitle><date>2020-04</date><risdate>2020</risdate><volume>130</volume><issue>4</issue><spage>857</spage><epage>865</epage><pages>857-865</pages><issn>0023-852X</issn><eissn>1531-4995</eissn><abstract>Objective Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. Methods We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum‐based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. Results We identified 69 patients treated with a multimodal approach (IC, surgery, radiotherapy). Overall, 44 patients recurred (64%). Of those, 19 patients received salvage surgery, but only four remained disease‐free. Median overall survival (OS) was 62.5 months. Sinonasal neuroendocrine and small cell histotypes (P = 0.0085), neuroendocrine differentiation (P = 0.006), and lack of response to IC (P = 0.03) were associated with worse OS. In patients who recurred, median OS was 13 months since recurrence. Survival was longer in patients submitted to salvage surgery (44%) than in those receiving chemotherapy alone at recurrence (29.5 vs. 4.6 months). Patients with a clinical benefit after palliative chemotherapy had a longer median OS than those with disease progression (29.2 vs. 4.4 months; P &lt; 0.0001). Conclusion Globally, the prognosis of locally advanced epithelial sinonasal cancers is dismal, with worse outcomes for neuroendocrine lesions. In the recurrent setting, feasibility of salvage surgery and clinical benefit from palliative chemotherapy are associated with longer OS. A multimodal treatment strategy with IC seems to offer improved OS when compared with other retrospective series not employing such a therapeutic tool. Level of Evidence 4 Laryngoscope, 130:857–865, 2020</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>31369156</pmid><doi>10.1002/lary.28202</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1294-6859</orcidid><orcidid>https://orcid.org/0000-0002-5184-6140</orcidid><orcidid>https://orcid.org/0000-0002-1580-3928</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0023-852X
ispartof The Laryngoscope, 2020-04, Vol.130 (4), p.857-865
issn 0023-852X
1531-4995
language eng
recordid cdi_proquest_miscellaneous_2267742925
source Wiley-Blackwell Read & Publish Collection
subjects Chemotherapy
Head & neck cancer
induction chemotherapy
Medical prognosis
multimodal treatment
radiation
Sinonasal cancer
Surgery
title Locally advanced epithelial sinonasal tumors: The impact of multimodal approach
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T03%3A30%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Locally%20advanced%20epithelial%20sinonasal%20tumors:%20The%20impact%20of%20multimodal%20approach&rft.jtitle=The%20Laryngoscope&rft.au=Orlandi,%20Ester&rft.date=2020-04&rft.volume=130&rft.issue=4&rft.spage=857&rft.epage=865&rft.pages=857-865&rft.issn=0023-852X&rft.eissn=1531-4995&rft_id=info:doi/10.1002/lary.28202&rft_dat=%3Cproquest_cross%3E2378200450%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3572-8fb833f153996a5084400a909badb073b541a2f744ebbe71b571e70cca62214f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2378200450&rft_id=info:pmid/31369156&rfr_iscdi=true